HIV Infection and Compromised Mucosal Immunity: Oral Manifestations and Systemic Inflammation

Abstract

Mucosal surfaces account for the vast majority of HIV transmission. In adults, HIV transmission occurs mainly by vaginal and rectal routes but rarely via oral route. By contrast, pediatric HIV infections could be as the result of oral route by breastfeeding. As such mucosal surfaces play a crucial role in HIV acquisition, and spread of the virus depends on its ability to cross a mucosal barrier. HIV selectively infects, depletes, and/or dysregulates multiple arms of the human immune system particularly at the mucosal sites and causes substantial irreversible damage to the mucosal barriers. This leads to microbial products translocation and subsequently hyper-immune activation. Although introduction of antiretroviral therapy (ART) has led to significant reduction in morbidity and mortality of HIV-infected patients, viral replication persists. As a result, antigen presence and immune activation are linked to “inflammaging” that attributes to a pro-inflammatory environment and the accelerated aging process in HIV patients. HIV infection is also associated with the prevalence of oral mucosal infections and dysregulation of oral microbiota, both of which may compromise the oral mucosal immunity of HIV-infected individuals. In addition, impaired oral immunity in HIV infection may predispose the patients to periodontal diseases that are associated with systemic inflammation and increased risk of cardiovascular diseases. The purpose of this review is to examine existing evidence regarding the role of innate and cellular components of the oral cavity in HIV infection and how HIV infection may drive systemic hyper-immune activation in these patients. We will also discuss current knowledge on HIV oral transmission, HIV immunosenescence in relation to the oral mucosal alterations during the course of HIV infection and periodontal disease. Finally, we discuss oral manifestations associated with HIV infection and how HIV infection and ART influence the oral microbiome. Therefore, unraveling how HIV compromises the integrity of the oral mucosal tissues and innate immune components of the oral cavity and its association with induction of chronic inflammation are critical for the development of effective preventive interventions and therapeutic strategies.

Introduction

HIV infection continues to be a major global health issue with an estimated 36.7 million people living with HIV worldwide (1). Sadly, 1.1 million people died of HIV or HIV-related comorbidities in 2015 alone (1). The development of antiretroviral therapy (ART) in 1995 was a significant step in the fight against HIV and because of ARTs, HIV no longer is a death sentence (2). However, HIV-infected individuals successfully treated with ART do not achieve normal longevity, as the viral replication is suppressed but not completely eliminated (3–6). Long-term HIV infection, even in the presence of ART, is associated with an accelerated onset of non-HIV-related comorbidities typically related to aging, including cardiovascular diseases (CVDs), osteoporosis, cancer, neurocognitive impairment, metabolic disorders, and frailty (7–9). Viral persistence in the face of therapy has been explained by, viral latency, lowered effectiveness of drugs in some anatomical sites and cell types, and cell-to-cell spread of the virus (4). As a result, antigen presence due to HIV infection represents the major factor in the induction of inflammation and immune activation, both of which are linked to “inflammaging” (4, 10). This concept attributes to a pro-inflammatory environment and the aging process.

The persistence of immune activation and a pro-inflammatory environment is in part thought to be due to the leakiness of the gastrointestinal (GI) tract (4, 6). The GI tract is an important site of HIV pathogenesis and, early in the disease, associated with massive depletion of CD4⁺ T cells, causing irreparable destruction of the epithelial lining and damage to the immunological compartments of the GI tract (11, 12). Among CD4⁺ T-cells, T helper 17 (Th17) cells mediate immunity against pathogens at mucosal surfaces; their depletion from the gut of HIV-infected individuals increases intestinal permeability and leads to microbial translocation (13). Thus, systemic translocation of the GI tract microbial products is thought to directly stimulate the immune system and exacerbate inflammation associated with non-AIDS comorbidities (14). Microbial translocation in HIV-infected individuals has been linked to preferential depletion of lymphocytes capable of producing the effector cytokines: IL-17 and IL-22 (4, 14, 15). It is unclear as to why the gut mucosa fails to recover even after the commencement of ART. Since the gut-associated lymphoid tissue (GALT) is so similar in structure and in resident immune cells to the mucosal-associated lymphoid tissue of the oral cavity (16), it could be hypothesized that HIV infection may result in the induction of similar patterns of destruction in the oral mucosal tissues. Oral mucosal immune cells express a wide range of pathogen-recognition receptors (PRRs) and metabolic sensors that act either as suppressors or activators (17). It is unclear whether immunological changes following HIV infection compromise the integrity of physical barrier in the oral cavity and enhance microbial products translocation, which subsequently contribute in the induction of chronic inflammation. Perhaps it is possible to propose a relationship between chronic inflammation of the oral cavity, such as periodontal disease, and systemic hyper-immune activation that has been linked to accelerated aging in HIV-infected individuals.

Periodontal disease is common among adults and characterized by chronic inflammation of the oral mucosa. This disease is caused by the interplay between the pathogenic microorganisms and host defense that can lead to microbial translocation and increased risk of inflammatory conditions, such as CVD (18, 19). Studies have shown that between 50 and 70% of adults will be diagnosed with periodontal disease during their lifetime (20, 21). The prevalence of periodontal disease may result in serious oral inflammatory conditions in general, and particularly for immunocompromised individuals (22, 23). It has been shown that people living with HIV are simultaneously more likely than their HIV-negative counterparts to have serious oral health issues such as oral candidiasis, hairy leukoplakia, warts, aphthous ulcers, and herpes even in the presence of ART (24, 25). Thus, the potential impact of poor oral health in HIV-infected individuals on the induction of systemic inflammation, which could be associated with accelerated aging needs to be further studied.

Establishing the differences in the cellular and molecular components of the innate immunity of the oral cavity between HIV-infected and non-infected individuals especially in regards to activation markers, expression of PRRs, cytokines, chemokines, and host defense peptides (HDPs) may offer new opportunities to prevent oral inflammation and subsequently reduce the risk of systemic inflammation in this vulnerable population. This review focuses on the innate immune components of the oral cavity with regard to HIV infection, the key markers associated with periodontal disease, the current understanding of oral inflammation in HIV infection, as well as evaluates interventions that might be utilized to improve oral health of HIV-infected individuals.

Innate Immune Components of Saliva

The oral cavity is a unique and sophisticated anatomical structure, characterized by a combination of soft and hard tissues, which is exposed tremendously and constitutively to external stimuli (16, 26, 27). As a result, the oral cavity is well served by numerous protective innate immune mechanisms. The oral innate immune response can be divided into secretory and cellular components. For instance, presence of numerous small and large salivary glands within the oral cavity protects us from a wide range of potential microorganisms that we are constantly exposed to through our mouth. Secretory components of the oral cavity include IgA, lysozymes, and HDPs such cathelicidins, defensins, and histatins are essential for mucosal immunity (Table 1). On the other hand, cellular innate immune components of the oral cavity are mainly epithelial cells, intraepithelial lymphocytes, granulocytes, tissue macrophages, and natural killer cells that play a crucial role in oral immunity (28). Dendritic cells (DCs) are another cellular components of the oral cavity that constantly surveying the area and are mainly found within the oral mucosa but can also be detected in the saliva (29, 30). Human saliva contains a vast amount of proteins that each has unique functions. Some proteins assist in lubrication or associate with the initiation of the digestion process, while others are involved in maintaining homeostasis and combatting pathogenic bacteria (31). Although saliva only has about 30% of the proteins normally seen in blood, it is commonly being used for diagnostic purposes in different conditions (32, 33).

Whole saliva is made up oral fluids from the major and minor salivary glands as well as from the gingival crevicular fluid and serum transudate from the mucosa (55). It may also contain fluids from areas of inflammation, immune and epithelial cells, food debris, and microbes (55, 56).

Saliva can be collected with or without stimulation. Saliva that is stimulated can have a different pH value when compared to unstimulated saliva, as well as has an increased volume of water content (55). However, unstimulated saliva can be difficult to collect if the individual does not produce a lot of saliva, either from dehydration, diet, age, gender, or from the side effects of medications (56). In 2010, Miller et al. found that unstimulated whole saliva allowed for the identification of several different biomarkers that were relevant to the assessment of cardiovascular and periodontal disease (55) (Table 2). These biomarkers are generally detected at lower levels than found in serum; however, there are some that appear at higher concentrations. Common detected analytes include tumor necrosis factor (TNF)-α, IL-1β, IL-6, fractalkine, growth-regulated oncogene 1-α, and monocyte chemotactic protein-1 (55). Elevation of IL-6, osteonectin, IL-1β, IL-8, MIP-1α, and MIP-1β in the saliva in acute inflammation has been reported and are elevated in the saliva of subjects 6–9 months prior to detection of bone loss compared to the saliva of individuals who remained healthy (57, 58).

There is some concern as to whether salivary proteases may degrade cytokines and decrease their ability to be detected; however, several studies have shown that the addition of protease inhibitors prior to freezing of saliva specimens does not impact the levels of detectable biomarkers in the saliva (56, 57). In addition, it has been reported that these inhibitors may interfere with the downstream analytical biomarker assays (84). It has also been shown that protein degradation in saliva is a rapid process, and the protein breakdown was not affected by the addition of sodium azide to the saliva samples (85). Similar observations were made following incubation with or without protease inhibitor. For instance, the addition of a protease inhibitor reduced detectable biomarkers from 26 to 19 compared with saliva samples when no inhibitor was added (85). This determines that protein degradation still occurs even in the presence of inhibitors, and therefore, saliva centrifugation and freezing the supernatant at −80°C as soon as possible is the best approach for maintaining its integrity (56, 84–86).

In addition to their main role in immunoregulation, these cytokines and proteins that are produced by infiltrating immune cells stimulate local osteoclasts which, in turn, induce alveolar bone resorption. Chronic inflammation of the alveolar mucosa is initiated by the intricate subgingival biofilm made up of opportunistic microorganisms and commensal bacteria (87). In response to these pathogens, inflammatory cells and gingival resident cells release destructive cytokines and proteinases that can damage gingival ligaments and initiate bone resorption (30, 34, 47). For example, IL-1β and IL-6 are found to be directly proportional to bone loss, where osteonectin is inversely proportional to bone loss (57). IL-8 is found at higher amounts than IL-6 and IL-1β in bone loss patients; however, MIP-1α may be the best biomarker to identify periodontal disease (58). In the elderly population, these markers will indicate the presence of periodontitis, since periodontal disease is more common in aging patients (88–90).

Innate Immune Components of the Oral Cavity and HIV

HIV infection appears to directly or indirectly impact the systemic and local innate immunity leading to oral opportunistic infections and malignancies (91). For instance, higher expression of oral cytokeratin in HIV-infected individuals and patients on ART has been reported, which indicates transformation of the oral mucosa and increased risk of malignancy (92).

As indicated in Figure 1, there are several secretory components of saliva that has antiviral and specifically anti-HIV activities. These components include cathelicidins, defensins, lactoferrin, lysozyme, and secretory leukocyte protease inhibitor (SLPI) (38–41, 44, 45, 48, 49, 52–54, 93–95). Cathelicidins are small cationic peptides that express antimicrobial activity and found in several tissues including the lungs, intestine, mucosa, skin, and oral cavity (41). They are predominantly found in the granules of neutrophils, mast cells, lymphocytes, keratinocytes, and epithelial cells (41). A domain of cathelicidin, LL-37, inhibits HIV replication in peripheral blood mononuclear cells and is currently being evaluated to determine if the same domain inhibits HIV in saliva (41, 96). Human β-defensins (hBD) are constitutively expressed by oral epithelium and some immune cells and hBD-2 and -3 are shown to inhibit HIV replication (45). Defensins inhibit HIV by directly binding to the virus as well as by downregulating the expression of CXCR4 on the cell surface (45). Lactoferrin is an iron-binding glycoprotein with strong anti-HIV activity (97). In one study, Kazmi et al. incubated whole saliva with an antilactoferrin antibody and determined that there was a reduction in HIV inhibition activity by 65% when compared to incubation with an IgG control (97). However, the exact mechanism by which lactoferrin inhibits HIV in saliva is still unclear. Lysozyme is another components of the saliva with antiviral activity. It is produced by the salivary glands, in particular the sublingual salivary gland, as well as by neutrophils, macrophages, and is found in the gingival crevicular fluids (98). It is speculated that the antiviral activity of lysozyme may be due to the degradation of viral polysaccharides and RNA transcripts (99). SLPI is a ubiquitous protein produced by macrophages, neutrophils, epithelial cells, and the acinar cells of parotid, submandibular, and submucosal glands (40). It is ambiguous as to how SLPI inhibits HIV infection in the saliva; however, it appears to involve the host cell instead of binding to the virus (53). SLPI may inhibit a step of viral infection that occurs once the virus has bound to the cell but before reverse transcription occurs (100).

Figure 1

Salivary function and composition are altered with HIV infection and some salivary components such as lactoferrin and IgA levels are altered in HIV patients with oral candidiasis compared with healthy subjects (111, 112). For example, frequent oral infections in HIV patients have been linked to significant reduction in lactoferrin and secretory IgA production by parotid glands (113).

Thus, innate immune salivary components exhibit a wide range of anti-HIV activities; however, any deficiency in their secretion and activity may enhance HIV-replication/acquisition in the oral cavity.

Immuno-Phenotypes of the Oral Cavity

The oral epithelium provides a physical barrier that protects underlying tissues from infection by pathogenic microorganisms as well as the effects of environmental threats. The oral mucosa is the port of entry into the GI tract where immune homeostasis is an important feature of the epithelial lining. The high permeability of the oral mucosa results in consistent contact between potentially harmful and harmless antigens with resident immune cells (27). As we mentioned earlier, the innate immune cells such as macrophages, natural killer cells, polymorphonuclear leukocytes, and DCs are present in the oral cavity and play important roles in mucosal immune tolerance (26).

Dendritic cells are professional antigen-presenting cells (APCs) that are divided into two subpopulations: myeloid DCs and plasmacytoid DCs (26, 114) (Table 3). These two populations of DCs differ in their expression of PRRs, in the types of cytokines they produce, and their mechanism of activating T cells. Myeloid DCs can be further divided into CD1c⁺ DCs and CD141⁺ DCs (26). A subset of CD11c⁺ myeloid cells are CD14⁺, or interstitial DCs (114). These DCs are more like monocytes or macrophages than conventional CD1c⁺ or CD141⁺ myeloid DCs and can express CD14⁺ but do not express costimulatory molecules (114). Langerhans cells (LCs), a subset of myeloid DCs, are positive for CD11c, MHC-II, as well as CD207 (langerin) (27). Oral LCs are positive for all the LC markers as well as CD1a. Oral LCs are permanent residents of the basal layer of the oral epithelium and are crucial in maintaining immune tolerance (115). Oral DCs can also express costimulatory molecules CD80 (B7.1), CD86 (B7.2), and CD40 as markers of activation (27). Plasmacytoid DCs generally lack all of the myeloid antigens (114). Identification of plasmacytoid DCs in healthy oral tissues has been a challenge, but they can be detected in inflammatory conditions in the oral cavity (116).

Mucosal DCs are the important component of oral tolerance as they have to maintain a homeostatic environment. DCs have to initiate a proper immune response against foreign and invasive pathogens, while preventing unnecessary activation of the immune system in response to commensal bacteria or food particles. Resident DCs are found throughout the oral mucosal epithelium but are most abundant in the vestibule, buccal mucosa, and hard palate (27). The morphology and density of DCs are proportional to age and tend to decrease as age increases; however, the number of DCs and maturation stage increases in the presence of inflammation (120).

While the oral cavity is enriched with APCs due to the abundance of food and microbial antigens, T cells are seen in very low frequency in the saliva and at the oral mucosal surfaces but B cells are almost absent in healthy patients. However, in the buccal tissues, CD4⁺ helper T cells are the dominant cell populations followed by CD8⁺ T cells and a small percentage of γδ T cells (121). We have already shown that γδ T cells are abundant in the oral cavity and play a protective role against oral candidiasis, which is one of the opportunistic fungal diseases associated with HIV infection (122). Among these CD4⁺ T cells, about 10–15% of them are Foxp3⁺, assumed to be T regulatory cells (Tregs) (121). This is important to mention that Foxp3 expression does not represent Tregs in human since activated CD4⁺ T cells may also express this marker. High levels of IFN-γ were found to be produced by both oral CD4⁺ and CD8⁺ T cells, but only 1–2% of CD4⁺ T cells secrete IL-17 (121). However, IL-13 and IL-22 were not detected in healthy oral mucosa (121). When comparing healthy controls to individuals with periodontal disease, it was found that CD3⁺ T cells remained the largest population; and interestingly the B cell population, which was nearly absent in the healthy population, became evident in the individuals with periodontal disease (121).

Neutrophils play a crucial role in innate defense as they contain and eliminate invading organisms after breaching host anatomical barriers, such as the skin and mucosa. Although they are found in abundance in the oral cavity of healthy individuals, periodontal disease results in a significant increase in CD15⁺CD16⁺ neutrophils in the oral cavity (121). They are required to ensure homeostatic conditions in the oral cavity. A harmonic balance of neutrophils is crucial in order to keep bacterial numbers in check as too many or too few neutrophils can lead to periodontal tissue damage (123). An increase in neutrophils is linked to an upregulation of IL-17, which has been shown to be associated with bone loss in animal models of periodontal disease (124). Although secretion of IL-17 is predominantly produced by CD4⁺ T cells (121), secretion of IL-17 by CD4⁺ T cells creates a positive feedback loop in the area of inflammation as IL-17 promotes neutrophil recruitment and also attracts more IL-17-producing CD4⁺ T cells (123). This generates a vicious cycle where inflammation persists indefinitely. In addition to the secretion of IL-17 by CD4⁺ T cells, they also produce an array of Th1- and Th2-type cytokines such as IFN-γ, IL-6, IL-13, and sometimes IL-10 (125–127). IL-6 and IFN-γ are pro-inflammatory cytokines that have been linked to the stimulation of osteoclastic resorption in periodontitis (126–128). IL-10 and IL-13 are both anti-inflammatory cytokines, which serve to inhibit bone resorption (101). This balance of cytokines ensures homeostasis of the periodontium; however, when this balance is disrupted by pathogens such as Porphyromonas gingivalis or Aggregatibacter actinomycetemcomitans, the paradigm can be shifted toward a Th1 response and induction of bone resorption (126, 128). This indicates that an increase in activated CD4⁺ T cells is associated with bone loss and disease progression.

The innate immune cells are the first line of defense against invasive pathogens and rely on a large group of PRRs, which discriminate different pathogens through recognition of conserved evolutionary molecular motifs, called pathogen-associated molecular patterns (PAMPs) (101). Among the PRRs, TLRs have been studied most widely. Upon PAMP engagement, PRRs trigger intracellular signaling cascades eventually culminating in the expression of a wide range of pro-inflammatory molecules, which together orchestrate the innate immune response to infection, and also is a prerequisite for the subsequent induction of adaptive immunity (101, 129, 130). TLRs are expressed by various cells such as endothelial cells, epithelial cells, gingival fibroblasts, and several APCs (101).

Of the 10 TLRs that are known to exist in humans, TLR2 and TLR4 are seen most abundantly in the oral cavity (130–133). TLR4 recognizes LPS, where TLR2, along with TLR1/TLR6 recognizes lipopeptides, peptidoglycans, lipotechoic acid, and unmodified protein structures (130, 134, 135). Evidence suggests that both TLR2- and TLR4-positive cells are upregulated in the gingival tissues in periodontitis (17, 130, 131, 133). Binding of TLR2 and TLR4 to PAMPs presented on pathogens will induce the expression of ICAM-1 and LFA-1 in the oral cavity which can lead to downstream bone resorption and increase in the rate of periodontitis (101).

Nucleotide-binding oligomerization domain-like receptors (NOD-like receptors) are another member of PRRs. They are intracellular sensors that detect PAMPs and endogenous molecules and can be upregulated similar to TLRs upon stimulation by bacterial components (102, 136). They can also sense danger-associated molecular pattern molecules that are associated with cell stress and can induce an inflammatory response in the absence of infection (102). NOD1 is ubiquitously expressed within various cells such as mononuclear cells, macrophages, DCs, and intestinal epithelial cells, while NOD2 is expressed mostly in phagocytic cells and intestinal Paneth cells (102, 103). It has been shown that NOD1 is involved in the recognition of Gram-negative bacteria confirming that this receptor is expressed on epithelial cells since these types of bacteria are commonly found to threaten epithelial cell linings (104).

Oral epithelial cells constitutively express NOD1 and NOD2, which induce the production of antimicrobial products such as beta-defensin and peptidoglycan-recognition proteins (105). Interestingly, NOD1 and NOD2 do not induce pro-inflammatory cytokines when stimulated (106). This may suggest that these pattern-recognition molecules on oral epithelial cells actively contribute in the removal of bacterial components without initiating an inflammatory response in the oral mucosa (105).

The innate immune cells of the oral cavity are a crucial component in protecting underlying mucosal tissues as well as the entrance of the GI tract. During homeostasis, these cells work together seamlessly to protect the oral mucosa without initiating unnecessary inflammatory responses. Disruption of this homeostatic state by pathogenic bacteria could result in periodontitis and subsequently to the translocation of bacterial products into the bloodstream that may lead to systemic inflammation and potentially CVDs (107, 108). Therefore, any inflammatory condition in the oral cavity (e.g., periodontal disease) would result in the recruitment of different immune cells including HIV-target cells into the mucosal sites which may facilitate oral HIV-transmission. On the other hand, immune deficiency associated with HIV infection could impair innate immune responses in the oral cavity and predisposes the host to opportunistic infections.

Oral Transmission of HIV

HIV transmission via the oral cavity has been a debatable concept. Multiple studies have failed to isolate the virus in the oral epithelial cells, and therefore, absence of virus in the oral cavity makes its transmission questionable (24, 28, 91, 137). Therefore, it has been thought that the risk of contracting HIV during oral sex is very low and antimicrobial peptides, such as human beta defensins and SLPI, have been implicated with the low rate of oral HIV transmission (138, 139). Orogenital transmission predominantly occurs via receptive oral sex; however, it seems to be very rare (95). The risk of acquiring HIV from receptive oral sex with a HIV-positive partner has been estimated to be between 0.04 and 0.06% (95). Acquiring HIV during receptive anal sex has been estimated to be 1.4% and contracting HIV via intravenous drug injection has been speculated at 0.63–2.4% (140, 141).

However, the controversy of oral transmission of HIV via receptive oral sex is continually examined. Contracting HIV via oral sex is difficult to determine because of lack of previous sexual history and that oral exposure rarely happens independently of other mucosal exposures. Studies investigating oral transmission of HIV have had small cohorts of high-risk individuals, making them insufficient to detect transmission by lower risk sexual behaviors (142). In one study, a homosexual couple reported engaging in only unprotected oral intercourse, and no other form of coition (143). The HIV-negative partner became seroconverted through this method; however, it is worth noting that this couple had only been sexually active for 1 month and it is unclear as to whether the seronegative partner could have unknowingly received HIV from a previous partner. Conversely, a study from 1990 to 2000 followed a cohort of heterosexual HIV-serodiscordant couples to determine if seroconversion occurred from unprotected oral intercourse (144). The 135 of 292 participants who were included in the study used condoms for vaginal or anal intercourse but did not use protection for orogenital contact. In addition, the participants confirmed that no condoms broke or slipped during penetrative intercourse. There was over 19,000 unprotected orogenital contacts in the 10-year period, looking at both receiving and performing oral sex with an infected partner, without a single case of HIV transmission occurring (144).

It has been well documented that disrupted, damaged, or inflamed oral mucosal tissues impact the risk factor for oral HIV transmission (145–147). In fact, there is a higher prevalence of contracting HIV through oral intercourse if the partner performing the act on an HIV-infected individual is a crack-cocaine user (146). Oral sores, blisters, and cuts are likely to occur from the hot smoke, hot glass or metal pipestem, or from sharp edges of the glass pipestem (146).

Although possible to contract HIV through the oral cavity, it appears that the oral innate immunity plays an important role in preventing the viral infection. This may be due to the protective role of the oral mucosa and/or the anti-HIV molecules present in saliva. For instance, SLPI is a protein found in mucosal secretions originating from submucosal glands and epithelial cells lining mucosal surfaces (137). SLPI has been found to have anti-HIV properties and disrupt the virus from infecting macrophages (53, 54). Furthermore, removal of SLPI in whole saliva in vitro was found to decrease its antiviral activity (53). Compared to other mucosal secretions in the body including breast milk and seminal fluid, saliva has the highest levels of SLPI, where infectious viral levels could not be detected (137).

However, HIV infection impacts expression and secretion of oral innate immune molecules. For instance, levels of SLPI in HIV-infected individuals are found to be decreased (94). In addition to SLPI, other oral secretory components including beta-defensin, salivary agglutinin, and mucins, thrombospondin, acidic proline-rich proteins (PRPs), and polyanionic proteins exhibit antimicrobial activities (52, 95). Beta-defensin blocks HIV replication by directly interacting and blocking virion activity as well as by exerting a chemokine-like effect on CD184 (CXCR4) causing this coreceptor to internalize and downregulate (45). CD184 is one of the coreceptors utilized by the virus for cellular entry of CD4⁺ T cells. Both high- and low-molecular weight mucins (MG1, MG2), as well as salivary agglutinins bind to and dislodge the viral envelope glycoprotein, gp120, from virions which form defective viral particles that cannot infect host immune cells (93, 95). Thrombospondin, PRPs, and polyanionic proteins (such as albumins) block cell binding by interfering with the interaction between the cell and gp120 (95). Other factors of preventing HIV transmission may include physical blocking of the virus due to the high viscosity or viral lysis from low hypotonicity of saliva (148). Even though these antimicrobial factors are important in preventing HIV infection in the oral cavity, SLPI is considered to be the main factor in saliva to protect against HIV infection (53, 137) (Figure 1).

Although adults rarely seem to be infected with HIV via the oral cavity, it does appear to be a gateway for infectious HIV in postnatal vertical transmission (24). Newborns who are not infected in utero could acquire HIV via the oral cavity by ingesting infected vaginal secretions or amniotic fluids during delivery (149). In addition, transferring HIV from mother-to-infant via breast milk has a risk of about 16% (150). Even if viral RNA levels are relatively small, the volume of breast milk consumed in a day is quite large and there is repetitive exposure of the oral mucosa to the virus and any micro abrasion could facilitate the HIV transmission. It is still unclear as to where the transmission occurs but studies in neonatal rhesus macaque demonstrated that the oral mucosa, tonsils, upper GI tract, and stomach as possible targets for simian immunodeficiency virus (SIV) transmission (24).

Oral Mucosal Infections and HIV Infection

Oral mucosal infections, such as oropharyngeal candidiasis (OPC) or hairy leukoplakia, are commonly seen in HIV-infected individuals suggesting compromised oral mucosal immunity due to HIV infection (25, 91). In fact, studies have shown that 70–90% of individuals infected with HIV will develop at least one oral manifestation over their lifetime, and that the appearance of severe oral mucosal infections can be an indicative of progression to AIDS (151, 152). The commencement of ART does not alleviate all of these manifestations. For instance, a sixfold increase in the rate of human papillomavirus (HPV) infection, more commonly known as oral warts, has been reported with the onset of ART (153, 154). It is still unclear as to why ART decreases some oral lesions but increases others. As we discussed above, Th17 cells mediate immunity against pathogens at mucosal surfaces and are key players of barrier integrity (155). Th17 cells depleted from the gut of HIV-infected individuals can lead to microbial translocation and non-AIDS comorbidities. Th17 cells along with IL-22 stimulate epithelial cells to produce antimicrobial factors to eliminate fungi such as Candida albicans and other bacteria by promoting inflammation through induction of inflammatory cytokines, chemokines, and recruitment of neutrophils (156). Recently, it has been reported that Th17-associated cytokines, IL-17 and IL-23, are essential in protection against OPC and IL-17-induced neutrophil recruitment plays an instrumental role in defense against mucosal candidiasis (157) (Figure 2). Therefore, in addition to immunodeficiency due to CD4⁺ T cell depletion, it is possible to speculate that possible elimination or impairment of IL-17-producing cells in the oral mucosa in the course of HIV infection might be associated with susceptibility to OPC and other opportunistic infections. In addition, production of reactive oxygen species and nitrogen radicals such as nitric oxide (NO) can damage or inhibit the growth of C. albicans and in agreement we have shown that NO mediates protection against oral infection with C. albicans (122). In the oral cavity, NO is produced by endothelia, epithelia, and macrophages as well as certain bacteria and by abiotic acidification of nitrite (158). The release of NO by these cells limits the proliferation of C. albicans; however, in some cases, C. albicans expresses flavohemoglobin genes to resist against NO (158). Since NO plays an important role against C. albicans in the oral cavity, studying the potential effect of HIV infection on NO production and possible mutation of flavohemoglobin genes to resist NO in HIV-infected individuals merits further investigations.

Figure 2

As discussed above, the most common oral manifestations associated with HIV infection are OPC and oral warts. In a study of 142 ART naïve and HIV-infected patients, oral candidiasis was found to be the most prevalent oral manifestation, followed by melanotic hyperpigmentation, and then oral hairy leukoplakia (159). Once ART is prescribed, all cases of pseudomembraneous candidiasis, oral ulcers, and angular cheilitis are resolved after 3 months (159). However, oral hairy leukoplakia takes longer to respond to the medications but would generally decrease in size after the first month with the eventual disappearance by the end of 5 months (159). It has also been reported that protease inhibitors act directly on inhibiting the production and activity of a major virulence factor of C. albicans particularly involved in mucosal (oral and vaginal) candidiasis of HIV-infected individuals (160, 161). Generally, it is believed that reconstitution of the patient’s immune system, characterized by increased in CD4⁺ T cells and decline in viral load, results in the decline of opportunistic infections such as OPC. However, very few patients experience resolution of Kaposi’s sarcoma within the 5-month period post-ART treatment (159).

In another study conducted on 399 HIV-infected ART-naïve patients in India, males were shown to exhibit more oral manifestations over females with a ratio of 1.2:1 (162). Oral candidiasis was found in 77% of the subjects as the most prevalent disease. Erythematous candidiasis was observed to be twofold higher than pseudomembranous candidiasis (162). This is in contrast to another study conducted in a cohort of HIV-positive patients from the South of India (163). In both of these studies, Kaposi’s sarcoma was absent from the list of oral manifestations observed (162, 163). This may be due to homosexuality being a possible risk factor for Kaposi’s sarcoma, while heterosexual practice is the main mode of HIV transmission in Asia (162).

There is a higher probability of acquiring oral manifestations, specifically oral candidiasis, if the CD4 count is less than 200/µL, and therefore, it has been suggested that when a CD4 count is unavailable or unattainable, the presence of oral candidiasis may be a positive predictive value of HIV disease progression (154, 162). It is still unclear as to why oral manifestations resolve so quickly when ART is initiated, and even more uncertain why HPV gets worse. In addition to the increased prevalence of oral warts, HIV-positive individuals are experiencing a higher risk of developing HPV-associated head and neck squamous cell carcinomas and not seeing resolution after commencement of ART (164). HIV-seropositive individuals appear to have a 1.5- to 4-fold increased risk for HPV-associated head and neck cancer (164). It is known that the decline of CD4⁺ T lymphocytes causes the HIV-infected person to become highly susceptible to various infections including the wide range of opportunistic oral manifestations (154, 165). HIV infection may alter local cytokine production, impact oral microbiota, and subsequently virus-induced alterations in the local immune system can impact the mucosal immune response to different oral bacteria. These data suggest OPC susceptibility in HIV patients is predominantly immune based, whereas susceptibility to oral hairy leukoplakia and oral warts may be more associated with factors other than mucosal immune function.

Of interest, HIV-infected individuals are at greater risk of developing Epstein–Barr virus (EBV)-associated malignancy such as non-Hodgkin’s lymphoma (166). However, the potential role of oral innate immunity in pathogenesis of EBV-associated oral lesions in HIV-infected individuals is unknown and merits further investigations.

HIV and Oral Microbiome

The role of oral microbiota is HIV-infected individuals requires further attention as either the disease (HIV) or the treatment (ART) may impact diversity and composition of the oral microbiome. For instance, it has been shown that elevated viremia in untreated patients is associated with significantly higher proportions of potentially pathogenic Veillonella, Prevotella, Megasphaera, and Campylobacter species than in healthy controls (109). Interestingly, increased prevalence of these potential pathogens result in the diminished presence of commensal Streptococcus and Veillonella species (109). However, ART-treated individuals showed lower colonization in their oral cavity by Neisseria flavescens compared with healthy controls (109). Another study reported that microbial diversity in the oral cavity of HIV-infected individuals was lower than healthy controls, and this diversity was further reduced following ART treatment (23). By contrast, while the bacterial community composition of oral wash specimens was unchanged in HIV-infected compared with healthy controls, using a deep sequencing approach, a difference in fungal communities was observed (167). A recent study on HIV-infected individuals undergoing ART has reported similar oral microbiomes but significant difference in the composition of the oral cavity microbiota (168). This study found that Haemophilus parainfluenza, which has been implicated in opportunistic infections, was associated with the HIV-infected individuals (168). A most recent study utilizing Microarray and pyrosequencing techniques reported a significant difference in the prevalence and distribution of the saliva bacterial communities among HIV-infected individuals before and after initiation of ART (169). Interestingly, this study found that Actinomyces, Atopobium, and Aggregatibacter genera were significantly different from the baseline after ART (169). These evidence suggest that there is a shift in the oral microbiome and these changes might be associated with HIV infection and/or HIV-treatment and other oral manifestations associated with disease. One of the main limitations of these studies seems to be the limited number of studied subjects. Thus, additional studies on larger cohorts are required to better understand the potential role of HIV infection and/or HIV treatment of oral of microbiome. In addition, how these changes in the oral microbiome can impact on the onset of other opportunistic pathogens in the oral cavity.

Periodontal Disease and Systemic Inflammation

Inflammation has long been recognized as a powerful contributing factor for systemic conditions, such as CVDs including atherosclerosis, coronary heart disease, and thromboembolic events (107, 170–172). Despite the identification of risk factors such as diet, smoking, obesity, and low physical activity, CVD is still on the rise and attention has turned to other associating factors such as inflammation (108). Recently, a large body of evidence has shown that common oral infections may play an important role in atherosclerosis (170) and an increasingly common chronic inflammatory disease that is present in 10–15% of the world’s population is periodontitis (173).

Periodontitis is a more advanced form of gingivitis where the supporting tissues around the teeth including periodontal ligaments and alveolar bone are breaking down (173). Clinical signs include deepening of the periodontal pocket surrounding the tooth, loss of attachment including the gingival mucosa, which will progressively lead to loosening of the teeth and ultimately tooth loss. The etiology of periodontitis is generally caused by local factors, such as accumulation of dental biofilm from poor oral hygiene practices, but can also be a manifestation of certain systemic diseases. For example, there is a strong correlation between patients who have diabetes mellitus and an increased prevalence of severe periodontitis (173). It is not only more common in these patients but also the progression of periodontitis is more aggressive and rapid (173). In addition, individuals infected with HIV are more susceptible to developing periodontitis because of their compromised immune system. Acute necrotizing periodontitis can also be a manifestation of a newly infected individual with HIV (174). In fact, oral manifestations may be present in up to 50% of HIV-infected individuals, and up to 80% of those who have progressed to AIDS (174, 175).

Looking at periodontitis from a molecular perspective, it appears that the host’s immune system in response to pathogens secretes substantial amounts of pro-inflammatory cytokines, like IL-1β, TNF-α, and IL-6, along with tissue destructive mediators like oxygen intermediates and matrix metalloproteinases (172). The oral mucosal epithelial lining begins to ulcerate and forms an easy port of entry for microorganisms or their by-products into the blood stream (176). Many of these bacteria are Gram-negative, obligate anaerobes and can colonize at distant sites (177). Haraszthy et al. tested 50 samples from patients undergoing carotid endarterectomy to determine if any periodontal bacterial pathogens were present. Forty-four percent of the specimens were positive for at least one periodontal pathogen (177). This suggests that oral microorganisms can enter the blood stream and induce the development and progression of systemic inflammation that may lead to other complications such as CVD.

To further link CVD with periodontitis, specific markers have been examined. In a study of 7,735 cases of fatal and non-fatal coronary heart disease, C-reactive protein (CRP), serum amyloid A protein (SAA), and serum albumin were found to be associating factors with an increased risk of heart disease (107). CRP is produced by the liver and serves as a systemic marker of inflammation. In the general population, a CRP level of less than 1.0 mg/L indicates a low risk for CVD (178). A reading between 1.0 and 2.9 mg/L is an intermediate risk, and a reading greater than 3.0 mg/L is considered high risk (178). A CRP level above 10 mg/L is considered the threshold of significant inflammatory diseases such as cancer, tuberculosis, or an autoimmune disorder (179, 180). In another study of 5,552 participants, it was found that the mean CRP level was approximately one-third higher in subjects that clinically presented with periodontitis than compared to subjects with little or no signs of periodontitis (179). Similarly, significant increase in CRP levels was found in patients with higher levels of clinical attachment loss and bone loss than healthy controls (181). This supports the notion that periodontitis is associated with an increased CRP level that has been correlated with an increased risk of CVD.

In addition to CRP, it has been reported that SAA proteins are also elevated in patients with chronic periodontitis (182). SAA proteins are part of the apolipoproteins group produced mostly by the liver in response to an acute-phase stimulus like an infection (182). A pilot study comparing CRP and SAA levels found that both were elevated in periodontitis patients and SAA, along with CRP, are valuable markers to identify inflammatory conditions in patients (182). Serum albumin is another protein produced by the liver and the presence of inflammation will reduce albumin concentration by decreasing its rate of synthesis (35). The release of inflammatory cytokines, like IL-1, IL-6, and TNF-α during an infection or inflammation, can decrease serum albumin levels (35). In a longitudinal study of 600 subjects, it was found that patients with a serum albumin concentration below 4.0 g/dL had significantly higher rates of periodontitis than patients with a serum albumin concentration above 4.0 g/dL (35).

As discussed above, patients with periodontitis have higher levels of CRP and SAA and lower levels of serum albumin compared with healthy population. Therefore, these patients might be more prone to the development of CVD. We suggest that the saliva of HIV-infected individuals might have higher levels of CRP and SAA and lower levels of serum albumin but this needs to be further investigated. Thus, these individuals could be at a higher risk of CVD than their non-HIV counterparts because of their compromised immune system. Taken together, we propose that periodontitis and/or compromised oral immune system associated with HIV infection may result in a local inflammatory condition and microbial products translocation that leads to systemic inflammation (Figure 3). In addition, periodontitis and local inflammation in the oral cavity may facilitate HIV acquisition.

Figure 3

HIV and Immunosenescence

The term “immunosenescence” was first coined by Dr. Roy Walford in 1969 and published in his influential book, “The Immunologic Theory of Aging” (183). His work generated the basis for current ideas about immunological aging. In 1997, Pommier et al. initiated research on immunosenescence in HIV pathogenesis (184). This idea commenced due to the remarkable physiological and immunological similarities between HIV-infected individuals and the HIV-uninfected elderly. It has been observed that during aging, there is a decrease in T cell renewal coinciding with terminally differentiated T cells with shortened telomeres (185). These changes may be due to the downstream effects of immune activation and inflammation causing an overall compromised immune system, eventually leading to immunosenescence. This phenomenon has been observed in HIV-infected individuals at an early age, possibly due to the inflammatory conditions in the GI tract leading to systemic inflammation.

With the introduction of ART, a positive diagnosis of HIV is no longer considered a death sentence. Since HIV patients are now living longer, it has become more obvious that these patients are experiencing accelerated aging (110, 186–189). In other words, these individuals are facing complications that are observed within the elderly population but apparent in a much younger age. They experience non-AIDS related comorbidities, such as cancer, liver and kidney failure, osteoporosis, CVD, as well as neurocognitive decline (189).

One of the features of aging is a depletion in T cell regeneration in addition to terminally differentiated T cells with shortened telomeres (185). It is believed that these changes are due to immune activation and inflammation, leading to a general decline of the immune responses which, eventually translates to immunosenescence (190). A common feature in all of these complications is chronic inflammation which is a hallmark of age-associated comorbidities, as chronic inflammation and immune activation are common features of HIV disease.

The intestinal mucosal tissue is the initial site of HIV replication and acute phase of infection is associated with the vast depletion of CD4⁺ T cells in the gut due to either direct killing by the virus, or due to CD4⁺ T cells apoptosis (9, 191, 192). Unless ART is commenced, the loss of CD4⁺ T cells continues throughout the entire disease course (15). Elimination of CD4⁺ T cells, including Tregs and Th17 cells in the gut results in impairment of the mucosal immune system and the disruption of the GI immune functions (4, 193). Historically, it is observed that HIV-infected individuals experience lymphocyte depletion, malabsorption, and abnormalities of the GI mucosal function (14, 15). Vast changes in the immune system additionally lead to the loss of naïve and memory T cell pool, resulting in a disproportion of T cell phenotypes. This altered state of T cells can impair the homeostatic and regulatory state of the GI tract.

Once an individual is infected with HIV, the immune activation associated with the viral replication results in damage to the epithelial lining of the intestinal mucosa because the GALT contains the majority of CD4⁺ T cells in the body. The virus breaches the intestinal lining of the lamina propria to target and activate CD4⁺ T cells, macrophages, monocytes, and other lymphocytes (194). The activation of the lymphocytes in the gut and the immune response to the virus alters the physical barrier of the epithelial cells (9). The tight junctions of the epithelial cells become inflamed, and the spaces between the epithelial cells become permeable (15). This damage also includes the atrophy or blunting of intestinal villi and crypt hyperplasia (15, 195). Once this occurs, translocation of microbes and their by-products into the lamina propria from the lumen exacerbate inflammation by translocation of microbial products into the periphery (9, 15). The microbial by-products, such as LPS, flagellin, and CpG DNA, induce strong pro-inflammatory responses by activating NODs and TLRs (9). In turn, these directly stimulate peripheral macrophages and DCs to secrete large amounts of pro-inflammatory mediators such as IL-1β, IL-6, and TNF-α (189, 196). Once ART is initiated, these cytokine levels decline, indicating that active HIV replication is indirectly or directly related to this profound inflammatory response (189).

In addition, the gut-associated pathological alterations in HIV-infected individuals results in reduction of IL-17 and IL-22 (14, 15, 197). IL-17 and IL-22 are responsible for maintaining mucosal homeostasis in the GALT but severely compromised upon SIV infection (197). Thus, quantitative loss of Th17 and Th22 CD4⁺ T-cells has been reported to be associated with microbial translocation, systemic immune activation, and disease progression (197). Unfortunately, initiation of ART does not fully restore the functionality and reconstitution of these mucosal Th17, Th22, and Th17/Th22 T-cells (197). In addition to Th22, a subset of gut innate immune cells that express natural killer cell markers referred to as NK-22 provide an innate source of IL-22 and are present in murine mucosa-associated lymphoid tissues and appear in the small intestine lamina propria during bacterial infection (198). Therefore, these innate lymphoid cells (ILCs) are found in mucosa-associated lymphoid tissues and in lamina propria as another source of IL-17 and IL-22 (198). ILCs play fundamental roles in response to infection by producing and secreting cytokines essential for immune regulation, tissue homeostasis, and repair (198). These adaptive lymphoid cells produce several T cell-associated cytokines, but do not express several cell-surface markers commonly seen on other immune cell lineages (199). ILCs do not express a T cell receptor and thus, fail to respond to antigen (199). It appears that ILCs play a role in HIV pathogenesis since ILCs are depleted in the periphery of HIV-infected individuals at early stages of the disease in the absence of ART (200). It does not appear that ILCs are reconstituted if ART is commenced during chronic infection, but depletion of the ILCs can be avoided if ART is initiated during the acute stage of infection (200). However, currently there is no report on oral mucosal ILCs in HIV-infected individuals and whether HIV infection results in depletion of these cells in the oral mucosal as observed in the gut needs to be investigated.

Although depletion of IL-17 and IL-22 is correlated with the extent of microbial translocation, long-term non-progressors and elite controllers are shown to avoid microbial translocation and maintain good levels of CD4⁺ T cells including Th17 cells with low levels of CD4⁺ T cells activation in the gut (197, 201).

Concluding Remarks

HIV infection could be considered a mucosal disease of the GI tract. The host’s immune response at the mucosal surfaces is a key determinant for HIV acquisition and spread. Thus, compromised mucosal barriers integrity not only facilitates HIV infection but also translocates microbial products into the periphery, resulting in hyper-immune activation. Oral mucosal immunity is alerted during HIV infection, as a result this dysregulated and/or impaired mucosal barrier may predispose the patient to opportunistic infections and systemic inflammation. The studies discussed here evaluate the current knowledge of secretory and cellular components of the mucosal surfaces and their role on HIV pathogenesis. In addition, HIV oral transmission in both infants and adults are discussed and the potential association of periodontal disease with HIV and other opportunist infections are analyzed. Understanding immunological changes at the mucosal compartments, in particular in the oral cavity of HIV-infected individuals in the presence or absence of ART, may assist us to develop novel interventions that may reduce mucosal-associated inflammation. However, further studies are required to determine how the impaired mucosal integrity of oral mucosa due to HIV infection can be prevented or restored. It is likely that such studies of basic mechanisms of oral mucosal barriers and immunological alterations will be essential to provide a foundation for the development of immune therapeutics that can effectively prevent mucosal-associated hyper-immune activation.

References

• 1

  GARPR. UNAIDS 2016 Estimates. Global AIDS Response Progress Reporting. (2016). Available from: https://aidsreportingtool.unaids.org/static/docs/GARPR_Guidelines_2016_EN.pdf

  • Google Scholar

• 2

  PalellaFJDelaneyKMMoormanACLovelessMOFuhrerJSattenGA. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med (1998) 338(13):853–60.10.1056/NEJM199803263381301

  • CrossRef
  • Google Scholar

• 3

  BoccaraFLangSMeulemanCEderhySMary-KrauseMCostagliolaDet alHIV and coronary heart disease, time for a better understanding. J Am Coll Cardiol (2013) 61:511–23.10.1016/j.jacc.2012.06.063

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4

  ElahiSWeissRHMeraniS. Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. AIDS (2016) 30:171–83.10.1097/QAD.0000000000000917

  • CrossRef
  • Google Scholar

• 5

  GuaraldiGOrlandoGZonaSMenozziMCarliFGarlassiEet alPremature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis (2011) 53(11):1120–6.10.1093/cid/cir627

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6

  LengSXMargolickJB. Understanding frailty, aging, and inflammation in HIV infection. Curr HIV/AIDS Rep (2015) 12(1):25–32.10.1007/s11904-014-0247-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7

  FaustoABongiovanniMCicconiPMenicagliLLigaboEVMelziSet alPotential predictive factors of osteoporosis in HIV-positive subjects. Bone (2006) 38(6):893–7.10.1016/j.bone.2005.11.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8

  HorvathSLevineAJ. HIV-1 infection accelerates age according to the epigenetic clock. J Infect Dis (2015) 212:1563–73.10.1093/infdis/jiv277

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 9

  NasiMPintiMDe BiasiSGibelliniLFerraroDMussiniCet alAging with HIV infection: a journey to the center of inflammAIDS, immunosenescence and neuroHIV. Immunol Lett (2014) 162(1):329–33.10.1016/j.imlet.2014.06.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10

  AbergJA. Aging, inflammation, and HIV infection. Top Antivir Med (2012) 20:101–5.

  • Pubmed Abstract
  • Google Scholar

• 11

  SankaranSGuadalupeMReayEGeorgeMDFlammJPrindivilleTet alGut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci U S A (2005) 102(28):9860–5.10.1073/pnas.0503463102

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12

  NilssonJKinloch-de-LoesSGranathASonnerborgAGohLAnderssonJ. Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. AIDS (2007) 21:565–74.10.1097/QAD.0b013e3280117204

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13

  KimCJMcKinnonLRKovacsCMKandelGHuibnerSChegeDet alMucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol (2013) 191(5):2164–73.10.4049/jimmunol.1300829

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14

  KlattNRChomontNDouekDCDeeksSG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev (2013) 254(1):326–42.10.1111/imr.12065

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15

  BrenchleyJMDouekDC. The mucosal barrier and immune activation in HIV pathogenesis. Curr Opin HIV AIDS (2008) 3(3):356–61.10.1097/COH.0b013e3282f9ae9c

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16

  WuRQZhangZFTuEChenQMChenW. The mucosal immune system in the oral cavity – an orchestra of T cell diversity. Int J Oral Sci (2014) 6:125–32.10.1038/ijos.2014.48

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17

  McClureRMassariP. TLR-dependent human mucosal epithelial cell responses to microbial pathogens. Front Immunol (2014) 5:386.10.3389/fimmu.2014.00386

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 18

  HumphreyLLFuRBuckleyDIFreemanMHelfandM. Periodontal disease and coronary heart disease incidence: a systematic review and meta-analysis. J Gen Intern Med (2008) 23:2079–86.10.1007/s11606-008-0787-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19

  LeishmanSJDoHLFordPJ. Cardiovascular disease and the role of oral bacteria. J Oral Microbiol (2010) 2(10):5781–94.10.3402/jom.v2i0.5781

  • CrossRef
  • Google Scholar

• 20

  DhadsePGattaniDMishraR. The link between periodontal disease and cardiovascular disease: how far we have come in last two decades?J Indian Soc Periodontol (2010) 14(3):148–54.10.4103/0972-124X.75908

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21

  EkePIDyeBAWeiLThornton-EvansGOGencoRJCDC Periodontal Disease Surveillance Workgroup: James Beck (University of North Carolina, Chapel Hill, USA)et alPrevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res (2012) 91(10):914–20.10.1177/0022034512457373

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22

  HolmstrupPGlickM. Treatment of periodontal disease in the immunodeficient patient. Periodontol (2000) 28(2002):190–205.10.1034/j.1600-0757.2002.280108.x

  • CrossRef
  • Google Scholar

• 23

  LiYSaxenaDChenZLiuGAbramsWRPhelanJAet alHIV infection and microbial diversity in saliva. J Clin Microbiol (2014) 52(5):1400–11.10.1128/JCM.02954-13

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24

  MalamudDWahlSM. The mouth: a gateway or a trap for HIV?AIDS (2010) 24(1):5–16.10.1097/QAD.0b013e328333525f

  • CrossRef
  • Google Scholar

• 25

  VaseliuNKamiruHNKabueM. Oral manifestations of HIV infection. Contemp Clin Dent (2010) 1:1–5.10.4103/0976-237X.62510

  • CrossRef
  • Google Scholar

• 26

  FellerLAltiniMKhammissaRAChandranRBouckaertMLemmerJ. Oral mucosal immunity. Oral Surg Oral Med Oral Pathol Oral Radiol (2013) 116:576–83.10.1016/j.oooo.2013.07.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27

  NovakNHaberstokJBieberTAllamJP. The immune privilege of the oral mucosa. Trends Mol Med (2008) 14(5):191–8.10.1016/j.molmed.2008.03.001

  • CrossRef
  • Google Scholar

• 28

  NittayanantaWTaoRJiangLPengYHuangY. Oral innate immunity in HIV infection in HAART era. J Oral Pathol Med (2016) 45:3–8.10.1111/jop.12304

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29

  HovavAH. Dendritic cells of the oral mucosa. Mucosal Immunol (2014) 7(1):27–37.10.1038/mi.2013.42

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30

  FabianTKHermannPBeckAFejerdyPFavianG. Salivary defense proteins: their network and role in innate and acquired oral immunity. Int J Mol Sci (2012) 13(4):4295–320.10.3390/ijms13044295

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31

  YoshizawaJMSchaferCASchaferJJFarrellJJPasterBJWongDT. Salivary biomarkers: toward future clinical and diagnostic utilities. Clin Microbiol Rev (2013) 26(4):781–91.10.1128/CMR.00021-13

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32

  SchulzBLCooper-WhiteJPunyadeeraCK. Saliva proteome research: current status and future outlook. Crit Rev Biotechnol (2012) 33:246–59.10.3109/07388551.2012.687361

  • CrossRef
  • Google Scholar

• 33

  KawasSARahimZHFergusonDB. Potential uses of human salivary protein and peptide analysis in the diagnosis of disease. Arch Oral Biol (2012) 57:1–9.10.1016/j.archoralbio.2011.06.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34

  DaleBAFredericksLP. Antimicrobial peptides in the oral environment: expression and function in health and disease. Curr Issues Mol Biol (2005) 7(2):119–33.

  • Pubmed Abstract
  • Google Scholar

• 35

  IwasakiMYoshihariAHirotomiTOgawaHHanadaNMiyazakiH. Longitudinal study on the relationship between serum albumin and periodontal disease. J Clin Periodontol (2008) 35(4):291–6.10.1111/j.1600-051X.2008.01215.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 36

  WalkerDM. Oral mucosal immunology: an overview. Ann Acad Med Singapore (2004) 33:27S–30S.

  • Pubmed Abstract
  • Google Scholar

• 37

  CzerkinskyCAnjuereFMcGheeJRGeorge-ChangyAHolmgrenJKienyMPet alMucosal immunity and tolerance: relevance to vaccine development. Immunol Rev (1999) 170:197–222.10.1111/j.1600-065X.1999.tb01339.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 38

  BrandtzaegP. Secretory immunity with special reference to the oral cavity. J Oral Microbiol (2013) 5:20401–25.10.3402/jom.v5i0.20401

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39

  DiamondGBeckloffNRyanLK. Host defense peptides in the oral cavity and the lung: similarities and differences. J Dent Res (2008) 87(10):915–27.10.1177/154405910808701011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 40

  DoumasSKolokotronisAStefanopoulosP. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun (2005) 73(3):1271–4.10.1128/IAI.73.3.1271-1274.2005

  • CrossRef
  • Google Scholar

• 41

  WongJHLegowskaARolkaKNgTBHuiMChoCHet alEffects of cathelicidin and its fragments on three key enzymes of HIV-1. Peptides (2011) 32(6):1117–22.10.1016/j.peptides.2011.04.017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42

  DorschnerRAPestonjamaspVKTamakuwalaSOhtakeTRudisillJNizetVet alCutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A streptococcus. J Invest Dermatol (2001) 117:91–7.10.1046/j.1523-1747.2001.01340.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 43

  MurakamiMOhtakeTDorschnerRAGalloRL. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J Dent Res (2002) 81:845–50.10.1177/154405910208101210

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44

  ChangTLKlotmanME. Defensins: natural anti-HIV peptides. AIDS (2004) 6:161–8.

  • Google Scholar

• 45

  Quinones-MateuMELedermanMMFengZChakrabortyBWeberJRangelHRet alHuman epithelial B-defensins 2 and 3 inhibit HIV-1 replication. AIDS (2003) 17:F39–48.10.1097/00002030-200311070-00001

  • CrossRef
  • Google Scholar

• 46

  KhurshidZNaseemMSheikhZNajeebSShahabSZafarMS. Oral antimicrobial peptides: types and roles in the oral cavity. Saudi Pharm J (2016) 24(5):515–24.10.1016/j.jsps.2015.02.015

  • CrossRef
  • Google Scholar

• 47

  BerluttiFPilloniAPietropaoliMPolimeniAValentiP. Lactoferrin and oral diseases: current status and perspective in periodontitis. Ann Stomatol (2011) 2(3–4):10–8.

  • Pubmed Abstract
  • Google Scholar

• 48

  LinALJohnsonDAPattersonTFWuYLuDLShiQet alSalivary anticandidal activity and saliva composition in an HIV-infected cohort. Oral Microbiol Immunol (2001) 16:270–8.10.1034/j.1399-302x.2001.016005270.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49

  ShineNKonopkaKDuzgunesN. The anti-HIV-1 activity associated with saliva. J Dent Res (1997) 76(2):634–40.10.1177/00220345970760020301

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 50

  EdgertonMKoshlukovaSE. Salivary histatin 5 and its similarities to the other antimicrobial proteins in human saliva. Adv Dent Res (2000) 14:16–21.10.1177/08959374000140010201

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 51

  JentschHSievertYGockeR. Lactoferrin and other markers from gingival crevicular fluid and saliva before and after periodontal treatment. J Clin Periodontol (2004) 31:511–4.10.1111/j.1600-051X.2004.00512.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 52

  JanaNKGrayLRShugarsDC. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. J Virol (2005) 79:6432–40.10.1128/JVI.79.10.6432-6440.2005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53

  McNeelyTBDealyMDrippsDJOrensteinJMEisenbergSPWahlSM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest (1995) 96:456–64.10.1172/JCI118056

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 54

  WahlSMMcNeelyTBJanoffENShugarsDWorleyPTuckerCet alSecretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-1. Oral Dis (1997) 3:S64–9.10.1111/j.1601-0825.1997.tb00377.x

  • CrossRef
  • Google Scholar

• 55

  MillerCSFoleyJDBaileyALCampbellCLHumphriesRLChristodoulidesNet alCurrent developments in salivary diagnostics. Biomark Med (2010) 4(1):171–89.10.2217/bmm.09.68

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 56

  SchipperRLoofAde GrootJHarthoornLDransfieldEvan HeerdeW. SELDI-TOF-MS of saliva: methodology and pre-treatment effects. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 847:45–53.10.1016/j.jchromb.2006.10.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 57

  NgPYDonleyMHausmannEHutsonADRossomandoEFScannapiecoFA. Candidate salivary biomarkers associated with alveolar bone loss: cross-sectional and in vitro studies. FEMS Immunol Med Microbiol (2007) 49(2):252–60.10.1111/j.1574-695X.2006.00187.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58

  FineDHMarkowitzKFairlieKTischio-BereskiDFerrandizJGodboleyDet alMacrophage inflammatory protein-1a shows predictive value as a risk marker for subjects and sits vulnerable to bone loss in a longitudinal model of aggressive periodontitis. PLoS One (2014) 9(6):e98541.10.1371/journal.pone.0098541

  • CrossRef
  • Google Scholar

• 59

  GoodsellDS. The molecular perspective: tumor necrosis factor. Oncologist (2006) 11(1):83–4.10.1634/theoncologist.11-7-849

  • CrossRef
  • Google Scholar

• 60

  ElahiSPangGAshmanRBClancyR. Nitric oxide-enhanced resistance to oral candidiasis. Immunology (2001) 104:447–54.10.1046/j.1365-2567.2001.01331.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61

  JoelTJSugunaSSteffiSR. Antimicrobial activity of lysozyme against oral pathogens. Asian J Pharm Res Health Care (2016) 8(2):42–6.10.18311/ajprhc/2016/662

  • CrossRef
  • Google Scholar

• 62

  SatoEJChoudhuryTNishikawaTInoueM. Dynamic aspect of reactive oxygen and nitric oxide in oral cavity. J Clin Biochem Nutr (2008) 42:8–13.10.3164/jcbn.2008002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 63

  BastosMFLimaJAVieiraPMMestnikMJFaveriMDuartePM. TNF-alpha and IL-4 levels in generalized aggressive periodontitis subjects. Oral Dis (2009) 15:82–7.10.1111/j.1601-0825.2008.01491.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 64

  MillerCSKingCPLangubMCKryscioRJThomasMV. Salivary biomarkers of existing periodontal disease: a cross-sectional study. J Am Dent Assoc (2006) 137(3):322–9.10.14219/jada.archive.2006.0181

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 65

  NohMKJungMKimSHLeeSRParkKHKimDHet alAssessment of IL-6, IL-8 and TNF-α levels in the gingival tissue of patients with periodontitis. Exp Ther Med (2013) 6(3):847–51.10.3892/etm.2013.1222

  • CrossRef
  • Google Scholar

• 66

  Tobon-ArroyaveSIJaramillo-GonzalezPEIsaza-GuzmanDM. Correlation between salivary IL-1B levels and periodontal clinical status. Arch Oral Biol (2008) 53(4):346–52.10.1016/j.archoralbio.2007.11.005

  • CrossRef
  • Google Scholar

• 67

  BoteroJEContrerasAParraB. Profiling of inflammatory cytokines produced by gingival fibroblasts after human cytomegalovirus. Oral Microbiol Immunol (2008) 23:291–8.10.1111/j.1399-302X.2007.00427.x

  • CrossRef
  • Google Scholar

• 68

  ImaiTHieshimaKHaskellCBabaMNagiraMNishimuraMet alIdentification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell (1997) 91(4):521–30.10.1016/S0092-8674(00)80438-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69

  MuehlhoeferASaubermannLJGuXLuedtke-HeckenkampKXavierRBlumbergRSet alFractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol (2000) 164(6):3368–76.10.4049/jimmunol.164.6.3368

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70

  TremblayKLemireMProvostVPastinenTRenaudYSandordAJet alAssociation study between the CX3CR1 gene and asthma. Genes Immun (2006) 7(8):632–9.10.1038/sj.gene.6364340

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71

  VolinMVHuynhNKlosowskaKChongKKWoodsJM. Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Atk. Arthritis Rheum (2007) 56:2512–22.10.1002/art.22806

  • CrossRef
  • Google Scholar

• 72

  HosokawaYNakanishiTYamaguchiDNakaeHMatsuoT. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in periodontal diseased tissue. Clin Exp Immunol (2005) 139:506–12.10.1111/j.1365-2249.2005.02675.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 73

  JonssonDAmistenSBratthallGHolmANilssonBO. LPS induces GROa chemokine production via NF-kB in oral fibroblasts. Inflamm Res (2009) 58:791–6.10.1007/s00011-009-0049-z

  • CrossRef
  • Google Scholar

• 74

  AlmasriAWisithphromKWindsorLJOlsonB. Nicotine and lipopolysaccharide affect cytokine expression from gingival fibroblasts. J Periodontol (2007) 78:533–41.10.1902/jop.2007.060296

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 75

  NelkenNACoughlinSRGordonDWilcoxJN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest (1991) 88:1121–7.10.1172/JCI115411

  • CrossRef
  • Google Scholar

• 76

  PradeepARDaisyHHadgeP. Gingival crevicular fluid levels of monocyte chemoattractant protein-1 in periodontal health and disease. Arch Oral Biol (2009) 54(5):503–9.10.1016/j.archoralbio.2009.02.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77

  VilligerPMTerkeltaubRLotzM. Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol (1992) 149:722–7.

  • Pubmed Abstract
  • Google Scholar

• 78

  YuXBarnhillRTGravesDT. Expression of monocyte chemoattractant protein-1 (MCP-1) in delayed type hypersensitivity reactions in the skin. Lab Invest (1994) 71:235–66.

  • Google Scholar

• 79

  YuXHAntoniadesHGravesDT. Expression of monocyte-chemoattractant protein-1 in human inflamed gingival tissues. Infect Immun (1993) 61:4622–8.

  • Google Scholar

• 80

  OzakiKHanazawaSTakeshitaAChenYWatanabeANishidaKet alInterleukin-1B and tumor necrosis factor-alpha stimulate synergistically the expression of monocyte chemoattractant protein-1 in fibroblastic cells derived from human periodontal ligament. Oral Microbiol Immunol (1996) 11(2):109–14.10.1111/j.1399-302X.1996.tb00344.x

  • CrossRef
  • Google Scholar

• 81

  RamVSParthibanSudhakarUMithradasNPrabhakarR. Bone biomarkers in periodontal disease: a review article. J Clin Diagn Res (2015) 9(1):ZE07–10.10.7860/JCDR/2015/11268.5438

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 82

  HanazawaSKawataYTakeshitaAKumadaHOkithuMTanakaSet alExpression of monocyte chemoattractant protein 1 (MCP-1) in adult periodontal disease: increased monocyte chemotactic activity in crevicular fluids and induction of MCP-1 expression in gingival tissues. Infect Immun (1993) 6(12):5219–24.

  • Pubmed Abstract
  • Google Scholar

• 83

  TerposEPolitouMViniouNRahemtullaA. Significance of macrophage inflammatory protein-1a (MIP-1a) in multiple myeloma. Leuk Lymphoma (2005) 46(12):1699–707.10.1080/10428190500175049

  • CrossRef
  • Google Scholar

• 84

  ThomadakiKHelmerhorstEJTianNSunXSiqueiraWLWaltDRet alWhole-saliva proteolysis and its impact on salivary diagnostics. J Dent Res (2011) 90(11):1325–30.10.1177/0022034511420721

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 85

  EsserDAlvarez-LlamasGde VriesMPWeeningDVonkRJRoelofsenH. Sample stability and protein composition of saliva. Implications for its use as a diagnostic fluid. Biomark Insights (2008) 3:25–37.

  • Pubmed Abstract
  • Google Scholar

• 86

  VastardisSLeighJEWozniakKYuknaRFidelPL. Influence of periodontal disease on Th1/Th2-type cytokines in saliva of HIV-positive individuals. Oral Microbiol Immunol (2003) 18:88–91.10.1034/j.1399-302X.2003.00045.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 87

  HoltSCEbersoleJL. Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia: the “red complex”, a prototype polybacterial pathogenic consortium in periodontitis. Periodontol (2000) 2005(38):72–122.10.1111/j.1600-0757.2005.00113.x

  • CrossRef
  • Google Scholar

• 88

  Abu EidRSawairFLandiniGSakuT. Age and the architecture of oral mucosa. Age (2012) 34(3):651–8.10.1007/s11357-011-9261-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 89

  BodineauACoulombBTedescoACSeguierS. Increase of gingival matured dendritic cells number in elderly patients with chronic periodontitis. Arch Oral Biol (2009) 54:12–6.10.1016/j.archoralbio.2008.06.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 90

  BoehmTKScannapiecoFA. The epidemiology, consequences and management of periodontal disease in older adults. J Am Dent Assoc (2007) 138(9):S26–33.10.14219/jada.archive.2007.0360

  • CrossRef
  • Google Scholar

• 91

  ChallacombeSJNaglikJR. The effects of HIV infection on oral mucosal immunity. Adv Dent Res (2006) 19:29–35.10.1177/154407370601900107

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 92

  NittayanantaWMitarnunWTalungchitSSriplungH. Changes in oral cytokeratin expression in HIV-infected subjects with long-term use of HAART. Oral Dis (2012) 18(8):793–801.10.1111/j.1601-0825.2012.01947.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 93

  NagashunmugamTMalamudDDavisCAbramsWRFriedmanHM. Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus. J Infect Dis (1998) 178(6):1635–41.10.1086/314511

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 94

  NittayanantaWKemapunmanusMYangngamSTalungchitSSriplungH. Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy. J Oral Pathol Med (2013) 42(3):208–15.10.1111/jop.12023

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 95

  ShugarsDCSweetSPMalamudDKazmiSHPage-ShaferKChallacombeSJ. Saliva and inhibition of HIV-1 infection: molecular mechanisms. Oral Dis (2002) 8(2):169–75.10.1034/j.1601-0825.8.s2.7.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96

  WangGWatsonKMBuckheitRWJr. Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins. Antimicrob Agents Chemother (2008) 52:3438–40.10.1128/AAC.00452-08

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 97

  KazmiSHNaglikJRSweetSPEvansRWO’SheaSBanatvalaJEet alComparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol (2006) 13(10):1111–8.10.1128/CDLI.00426-05

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 98

  VeermanECvan den KeybusPAVissinkANieuw AmerongenAV. Human glandular salivas: their separate collection and analysis. Eur J Oral Sci (1996) 104:346–52.10.1111/j.1600-0722.1996.tb00090.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99

  Lee-HuangSHuangPLSunYHuangPLKungHBlitheDLet alLysozyme and RNases as anti-HIV components in B-core preparations of human chorionic gonadotropin. Proc Natl Acad Sci U S A (1999) 96(6):2678–81.10.1073/pnas.96.6.2678

  • CrossRef
  • Google Scholar

• 100

  McNeelyTBShugarsDCRosendahlMTuckerCEisenbergSPWahlSM. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leucocyte protease inhibitor occurs prior to viral reverse transcription. Blood (1997) 90:1141–9.

  • Google Scholar

• 101

  HienzSAPaliwalSIvanovskiS. Mechanisms of bone resorption in periodontitis. J Immunol Res (2014) 2015(2014):1–11.10.1155/2015/615486

  • CrossRef
  • Google Scholar

• 102

  FranchiLWarnerNVianiKNunezG. Function of NOD-like receptors in microbial recognition and host defense. Immunol Rev (2010) 227(1):106–28.10.1111/j.1600-065X.2008.00734.x

  • CrossRef
  • Google Scholar

• 103

  FritzJHFerreroRLPhilpottDJGirardinSE. NOD-like proteins in immunity, inflammation and disease. Nat Immunol (2006) 7(12):1250–7.10.1038/ni1412

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 104

  KuferTABanksDJPhilpottDJ. Innate immune sensing of microbes by NOD proteins. Ann N Y Acad Sci (2006) 1072:19–27.10.1196/annals.1326.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 105

  UeharaATakadaH. Synergism between TLRs and NOD1/2 in oral epithelial cells. J Dent Res (2008) 87(7):682–6.10.1177/154405910808700709

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 106

  UeharaAFujimotoYFukaseKTakadaH. Various human epithelial cells express functional toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol (2007) 44:3100–11.10.1016/j.molimm.2007.02.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 107

  DaneshJWhincupPWalkerMLennonLThomsonAApplebyPet alLow grade inflammation and coronary heart disease: a prospective study and updated meta-analyses. BMJ (2000) 321:199–204.10.1136/bmj.321.7255.199

  • CrossRef
  • Google Scholar

• 108

  ZakynnthinosEPappaN. Inflammatory biomarkers in coronary artery disease. Int J Cardiol (2009) 53(3):317–33.10.1016/j.jjcc.2008.12.007

  • CrossRef
  • Google Scholar

• 109

  DangATCottonSSankaran-WaltersSLiC-SLeeC-YMDandekarSet alEvidence of an increased pathogenic footprint in the lingual microbiome of untreated HIV infected patients. BMC Microbiol (2012) 12:153.10.1186/1471-2180-12-153

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 110

  ArmahKAMcGinnisKBakerJGibertCButtAABryantKJet alHIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis (2012) 55:126–36.10.1093/cid/cis406

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 111

  EgusaHNikawaHMakihiraSYataniHHamadaT. In vitro mechanisms of interleukin-8-mediated responses of human gingival epithelial cells to Candida albicans infection. Int J Med Microbiol (2006) 296(4–5):301–11.10.1016/j.ijmm.2005.12.017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 112

  LinALJohnsonDASimsCAStephanKTYehCK. Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART). Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2006) 102(3):318–24.10.1016/j.tripleo.2005.07.021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 113

  MullerFHolberg-PetersenMRollagHDegreMBrandtzaegPFrolandSS. Nonspecific oral immunity in individuals with HIV infection. J Acquir Immune Defic Syndr (1992) 5(1):46–51.

  • Pubmed Abstract
  • Google Scholar

• 114

  CollinMMcGovernNHaniffaM. Human dendritic cell subsets. Immunology (2013) 140:22–30.10.1111/imm.12117

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 115

  ZavalaWDCavicchiaJC. Deterioration of the Langerhans cell network of the human gingival epithelium with aging. Arch Oral Biol (2006) 51:1150–5.10.1016/j.archoralbio.2006.06.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 116

  LukicAVasilijicSMajstorovicIVucevicDMojsilovicSGazivodaDet alCharacterization of antigen-presenting cells in human apical periodontitis lesions by flow cytometry and immunocytochemistry. Int Endod J (2006) 39:626–36.10.1111/j.1365-2591.2006.01125.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 117

  Al-SabbaghMAlladahALinYKryscioRJThomasMDEbersoleJLet alBone remodeling-associated salivary biomarker MIP-1a distinguishes periodontal disease from health. J Periodontal Res (2012) 47:389–95.10.1111/j.1600-0765.2011.01445.x

  • CrossRef
  • Google Scholar

• 118

  Ziegler-HeitbrockLAncutaPCroweSDalodMGrauVHartDNet alNomenclature of monocytes and dendritic cells in blood. Blood (2010) 116:e74–80.10.1182/blood-2010-02-258558

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 119

  BoltjesAvan WijkF. Human dendritic cell functional specialization in steady-state and inflammation. Front Immunol (2014) 5:131.10.3389/fimmu.2014.00131

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 120

  AliARautemaaRHietanenJBeklenAKonttinenY. A possible CD1a Langerhans cell-mast cell interaction in chronic hyperplastic candidosis. J Oral Pathol Med (2007) 36(6):329–36.10.1111/j.1600-0714.2007.00527.x

  • CrossRef
  • Google Scholar

• 121

  DutzanNKonkelJEGreenwell-WildTMoutsopoulosNM. Characterization of the human immune cell network at the gingival barrier. Mucosal Immunol (2016) 9(5):1163–72.10.1038/mi.2015.136

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 122

  ElahiSPangGClancyRAshmanRB. Cellular and cytokine correlates of mucosal protection in murine model of oral candidiasis. Infect Immun (2000) 68(10):5771–7.10.1128/IAI.68.10.5771-5777.2000

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 123

  Cortes-VieyraRRosalesCUribe-QuerolE. Neutrophil functions in periodontal homeostasis. J Immunol Res (2016) 2016:1396106.10.1155/2016/1396106

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 124

  EskanMAJotwaniRAbeTChmelarJLimJHLiangSet alThe leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol (2012) 13(5):465–73.10.1038/ni.2260

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 125

  FujihashiKYamamotoMHiroiTBambergTVMcGheeJRKiyoniH. Selected Th1 and Th2 cytokine mRNA expression by CD4+ T cells isolated from inflamed human gingival tissues. Clin Exp Immunol (1996) 103:422–8.10.1111/j.1365-2249.1996.tb08297.x

  • CrossRef
  • Google Scholar

• 126

  TaubmanMAKawaiT. Involvement of T-lymphocytes in periodontal disease and in direct and indirect induction of bone resorption. Crit Rev Oral Biol Med (2001) 12(2):125–35.10.1177/10454411010120020301

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 127

  TakeichiOHaberJKawaiTSmithDJMoroITaubmanMA. Cytokine profiles of T-lymphocytes from gingival tissues with pathological pocketing. J Dent Res (2000) 79(8):1548–55.10.1177/00220345000790080401

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 128

  CochranDL. Inflammation and bone loss in periodontal disease. J Periodontol (2008) 79:1569–76.10.1902/jop.2008.080233

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 129

  UnderhillDMOzinskyA. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol (2002) 14(1):103–10.10.1016/S0952-7915(01)00304-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 130

  MuthukuruMJotwaniRCutlerCW. Oral mucosal endotoxin tolerance induction in chronic periodontitis. Infect Immun (2005) 73(2):687–94.10.1128/IAI.73.2.687-694.2005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 131

  SugawaraYUeharaAFujimotoYKusomotoSFuakseKShibataKet alToll-like receptors, NOD1, and NOD2 in oral epithelial cells. J Dent Res (2006) 85(6):524–9.10.1177/154405910608500609

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 132

  UeharaASugawaraYTamaiRTakadaH. Contrasting responses of human gingival and colonic epithelial cells to lipopolysaccharides, lipoteichoic acids and peptidoglycans in the presence of soluble CD14. Med Microbiol Immunol (2001) 189:185–92.10.1007/s004300100063

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 133

  MoriYYoshimuriAUkaiTLienEEspevikTHaraY. Immunohistochemical localization of toll-like receptors 2 and 4 in gingival tissue from patients with periodontitis. Microbiol Immunol (2003) 18(1):54–8.10.1034/j.1399-302X.2003.180109.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 134

  TakedaKAkiraS. Microbial recognition by toll-like receptors. J Dermatol Sci (2004) 34:73–82.10.1016/j.jdermsci.2003.10.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 135

  NussbaumGBen-AdiSGenzierTSelaMRosenG. Involvement of toll-like receptors 2 and 4 in the innate immune response to Treponema denticola and its outer sheath components. Infect Immun (2009) 77(9):3939–47.10.1128/IAI.00488-09

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 136

  Oviedo-BoysoJBravo-PatinoABaizabal-AguirreVM. Collaborative action of toll-like and NOD-like receptors as modulators of the inflammatory response to pathogenic bacteria. Mediators Inflamm (2014) 2014:432785.10.1155/2014/432785

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 137

  MoutsopoulosNMGreenwell-WildTWahlSM. Differential mucosal susceptibility in HIV-1 transmission and infection. Adv Dent Res (2006) 19:52–6.10.1177/154407370601900111

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 138

  CervantesCAOliveiraLMManfrereKCLimaJFPereiraNZDuarteAJ. Antiviral factors and type I/III interferon expression associated with regulatory factors in the oral epithelial cells from HIV-1 serodiscordant couples. Sci Rep (2016) 6:1–8.10.1038/srep25875

  • CrossRef
  • Google Scholar

• 139

  BaggaleyRFWhiteRGBoilyMC. Systematic review of orogenital HIV-1 transmission probabilities. Int J Epidemiol (2008) 37:1255–65.10.1093/ije/dyn151

  • CrossRef
  • Google Scholar

• 140

  BaggaleyRFWhiteRGBoilyMC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol (2010) 39(4):1048–63.10.1093/ije/dyq057

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 141

  BaggaleyRFBoilyMCWhiteRGAlaryM. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS (2006) 20(6):805–12.10.1097/01.aids.0000218543.46963.6d

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 142

  WoodLFCharoudiAChenHLJaspanHBSodoraDL. The oral mucosa immune environment and oral transmission of HIV/SIV. Immunol Rev (2013) 254(1):1–34.10.1111/imr.12078

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 143

  TruongHHBerreyMMSheaTDiemKCoreyL. Concordance between HIV source partner identification and molecular confirmation in acute retroviral syndrome. J Acquir Immune Defic Syndr (2002) 29:232–43.

  • Google Scholar

• 144

  del RomeroJMarinovichBCastillaJGarciaSCampoJHernandoVet alEvaluating the risk of HIV transmission through unprotected orogenital sex. AIDS (2002) 16(9):1296–7.10.1097/00002030-200206140-00017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 145

  CampoJPereaMARomeroJDCanoJHernandoVBasconesA. Oral transmission of HIV, reality or fiction? An update. Oral Dis (2006) 12:219–28.10.1111/j.1601-0825.2005.01187.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 146

  FaruqueSEdlinBRMcCoyCBWordCOLarsenSASchmidDSet alCrack cocaine smoking and oral sores in three inner-city neighborhoods. J Acquir Immune Defic Syndr (1996) 13(1):87–92.10.1097/00042560-199609000-00012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 147

  WallaceJIPorterJWeinerASteinbergA. Oral sex, crack smoking, and HIV infection among female sex workers who do not inject drugs. Am J Public Health (1997) 87(3):470.10.2105/AJPH.87.3.470

  • CrossRef
  • Google Scholar

• 148

  BaronSPoastJCloydMW. Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes. Arch Intern Med (1999) 159:303–10.10.1001/archinte.159.3.303

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 149

  GaillardPVerhofstedeCMwanyumbaFClaeysPChohanVMandaliyaKet alExposure to HIV-1 during delivery and mother-to-child transmission. AIDS (2000) 14(15):2341–8.10.1097/00002030-200010200-00015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 150

  John-StewartG. Infant feeding and prevention of mother-to-child transmission of HIV-1. Curr Opin HIV AIDS (2008) 3:173–9.10.1097/COH.0b013e3282f50bc6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 151

  KamiruHNNaidooS. Oral HIV lesions and oral health behaviour of HIV-positive patients attending the Queen Elizabeth II Hospital, Maseru, Lesotho. SADJ (2002) 57(11):479–82.

  • Pubmed Abstract
  • Google Scholar

• 152

  PattonLLPhelanJARamos-GomezFJNittayanantaWShiboskiCHMbuguyeTL. Prevalence and classification of HIV-associated oral lesions. Oral Dis (2002) 8(2):98–109.10.1034/j.1601-0825.2002.00020.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 153

  GreenspanDCancholaAJMacPhailLACheikhBGreenspanJS. Effects of highly active antiretroviral therapy on frequency of oral warts. Lancet (2001) 357:1411–2.10.1016/S0140-6736(00)04578-5

  • CrossRef
  • Google Scholar

• 154

  MoodleyAWoodNH. HIV-associated oral lesions in HIV-seropositive patients at an HIV-treatment clinic in South Africa. J AIDS Clin Res (2015) 6:422.10.4172/2155-6113.1000422

  • CrossRef
  • Google Scholar

• 155

  WeaverCTElsonCOFouserLAKollsJK. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol (2013) 8:477–512.10.1146/annurev-pathol-011110-130318

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 156

  WeaverCTHattonRDManganPRHarringtonLE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol (2007) 25:821–52.10.1146/annurev.immunol.25.022106.141557

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 157

  HupplerARContiHRHernandez-SantosNDarvilleTBiswasPSGaffenSL. Role of neutrophils in IL-17-dependent immunity to mucosal candidiasis. J Immunol (2014) 192(4):1745–52.10.4049/jimmunol.1302265

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 158

  UllmannBDMyersHChiranandWLazzellALZhaoQVegaLAet alInducible defense mechanism against nitric oxide in Candida albicans. Eukaryot Cell (2004) 3(3):715–23.10.1128/EC.3.3.715-723.2004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 159

  TaiwoOOHassanZ. The impact of highly active antiretroviral therapy (HAART) on the clinical features of HIV-related oral lesions in Nigeria. AIDS Res Ther (2010) 7:19–25.10.1186/1742-6405-7-19

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 160

  CassoneATacconelliEDe BernardisFTumbarelloMTorosantucciAChianiPet alAntiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. J Infect Dis (2002) 185(2):188–95.10.1086/338445

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 161

  De BernardisFAranciaSMorelliLHubeBSanglardDSchaferWet alEvidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis (1999) 179(1):201–8.10.1086/314546

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 162

  BodhadeASGanvirSMHazareyVK. Oral manifestations of HIV infection and their correlation with CD4 count. J Oral Sci (2011) 53(2):203–11.10.2334/josnusd.53.203

  • CrossRef
  • Google Scholar

• 163

  RanganathanKReddyBVKumarasamyNSolomonSViswanathanRJohnsonNW. Oral lesions and conditions associated with human immunodeficiency virus infection in 300 south Indian patients. Oral Dis (2002) 6:152–7.10.1111/j.1601-0825.2000.tb00326.x

  • CrossRef
  • Google Scholar

• 164

  BeachlerDCD’SouzaG. Oral HPV infection and head and neck cancers in HIV-infected individuals. Curr Opin Oncol (2013) 25(5):503–10.10.1097/CCO.0b013e32836242b4

  • CrossRef
  • Google Scholar

• 165

  HilleJJWebster-CyriaqueJPalefskiJMRaab-TraubN. Mechanisms of expression of HHV8, EBV and HPV in selected HIV-associated oral lesions. Oral Dis (2002) 8(s2):161–8.10.1034/j.1601-0825.2002.00028.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 166

  CliffordGMPoleselJRickenbachMDal MasoLKeiserOKoflerAet alCancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst (2005) 97(6):425–32.10.1093/jnci/dji072

  • CrossRef
  • Google Scholar

• 167

  MukherjeePKChandraJRetuertoMSikaroodiMBrownREJurevicRet alOral mycobiome analysis of HIV-infected patients: identification of Pichia as an antagonist of opportunistic fungi. PLoS Pathog (2014) 10(3):e1003996.10.1371/journal.ppat.1003996

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 168

  KistlerJOArirachakaranPPoovorawanYDahlenGWadeWG. The oral microbiome in human immunodeficiency virus (HIV)-positive individuals. J Med Microbiol (2015) 64:1094–101.10.1099/jmm.0.000128

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 169

  MoyesDLSaxenaDJohnMDMalamudD. The gut and oral microbiome in HIV disease: a workshop report. Oral Dis (2016) 22(Suppl 1):166–70.10.1111/odi.12415

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 170

  EpsteinSEZhouYFZhuJ. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation (1999) 100(4):e20–8.10.1161/01.CIR.100.4.e20

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 171

  MejerNGotlandNUhreMLWesthHSchonheyderHCPetersenAet alIncreased risk of arterial thromboembolic events after Staphylococcus aureus bacteremia: a matched cohort study. J Infect Dis (2015) 71(2):167–78.10.1016/j.jinf.2015.03.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 172

  MoutsopoulosNMMadianosPN. Low-grade inflammation in chronic infectious diseases: paradigm of periodontal infections. Ann N Y Acad Sci (2006) 1088:251–64.10.1196/annals.1366.032

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 173

  PetersenPEOgawaH. The global burden of periodontal disease: towards integration with chronic disease prevention and control. Periodontol (2012) 60:15–39.10.1111/j.1600-0757.2011.00425.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 174

  CooganMMGreenspanJChallacombeSJ. Oral lesions in infection with human immunodeficiency virus. Bull World Health Organ (2005) 83:700–6.

  • Google Scholar

• 175

  PalmerGDRobinsonPGChallacombeSJBirnbaumWCroserDErridgePLet alAetiological factors for oral manifestations of HIV infection. Oral Dis (1996) 2:193–7.10.1111/j.1601-0825.1996.tb00223.x

  • CrossRef
  • Google Scholar

• 176

  LiXKollveitKMTronstadLOlsenI. Systemic diseases caused by oral infection. Clin Microbiol Rev (2000) 13(4):547–58.10.1128/CMR.13.4.547-558.2000

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 177

  HaraszthyVIZambonJJTrevisanMZeidMGencoRJ. Identification of periodontal pathogens in atheromatous plaques. J Periodontol (2000) 71(10):1554–60.10.1902/jop.2000.71.10.1554

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 178

  MacyEMHayesTETracyRP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem (1997) 43:52–8.

  • Pubmed Abstract
  • Google Scholar

• 179

  SladeGDGhezziEMHeissGBeckJDRicheEOffenbacherS. Relationship between periodontal disease and C-reactive protein among adults in the atherosclerosis risk in communities study. JAMA (2003) 163(10):1172–9.10.1001/archinte.163.10.1172

  • CrossRef
  • Google Scholar

• 180

  AllinKHNordestgaardBG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci (2011) 48(4):155–70.10.3109/10408363.2011.599831

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 181

  NoackBGencoRJTrevisanMGrossiSZambonJJDe NardinE. Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol (2001) 72(9):1221–7.10.1902/jop.2000.72.9.1221

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 182

  ArdilaCMGuzmanIC. Comparison of serum amyloid A protein and C-reactive protein levels as inflammatory markers in periodontitis. J Periodontal Implant Sci (2015) 45(1):14–22.10.5051/jpis.2015.45.1.14

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 183

  WalfordRL. The immunologic theory of aging. Gerontologist (1964) 4(4):195–7.10.1093/geront/4.4.195

  • CrossRef
  • Google Scholar

• 184

  PommierJ-PGauthierLLivartowskiJGalanaudPBoueFDulioustAet alImmunosenescence in HIV pathogenesis. Virology (1997) 231:148–54.10.1006/viro.1997.8512

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 185

  DesaiSLandayA. Early immune senescence in HIV disease. Curr HIV/AIDS Rep (2010) 7:4–10.10.1007/s11904-009-0038-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 186

  DubrowRSilverbergMJParkLSCrothersKJusticeA. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol (2012) 24(5):506–16.10.1097/CCO.0b013e328355e131

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 187

  LohseNHansenAEPedersenGKronborgGGerstoftJSorensenHT. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med (2007) 146:87–95.10.7326/0003-4819-146-2-200701160-00003

  • CrossRef
  • Google Scholar

• 188

  ManfrediR. HIV disease and advanced age. An increasing therapeutic challenge. Drugs Aging (2002) 19(9):647–69.10.2165/00002512-200219090-00003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 189

  DeeksSG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med (2011) 62:141–55.10.1146/annurev-med-042909-093756

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 190

  SalamNRaneSDasRFaulknerMGundRKandpalUet alT cell ageing: effects of age on development, survival and function. Indian J Med Res (2013) 138:595–608.

  • Google Scholar

• 191

  OkoyeAAPickerLJ. CD4+ T cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev (2014) 254(1):54–64.10.1111/imr.12066

  • CrossRef
  • Google Scholar

• 192

  MehandruSPolesMATenner-RaczKHorowitzAHurleyAHoganCet alPrimary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 200:761–70.10.1084/jem.20041196

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 193

  FevrierMDorghamKRebolloA. CD4+ T cell depletion in human immunodeficiency (HIV) infection: role of apoptosis. Viruses (2011) 3(5):586–612.10.3390/v3050586

  • CrossRef
  • Google Scholar

• 194

  NanniniECOkhuysenPC. HIV1 and the gut in the era of highly active antiretroviral therapy. Curr Gastroenterol Rep (2002) 4(5):392–8.10.1007/s11894-002-0009-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 195

  BrenchleyJMPriceDASchackerTWAsherTESilvestriGRaoSet alMicrobial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 12(12):1365–71.10.1038/nm1511

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 196

  AppayVSauceD. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol (2008) 214:231–41.10.1002/path.2276

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 197

  RyanESMicciLFromentinRPaganiniSMcGaryCSEasleyKet alLoss of function of intestinal IL-17 and IL-22 producing cells contributes to inflammation and viral persistence in SIV-infected rhesus macaques. PLoS Pathog (2016) 12(2):e1005412.10.1371/journal.ppat.1005412

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 198

  CellaMFuchsAVermiWFacchettiFOteroKLennerzJMet alA human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature (2009) 457:722–5.10.1038/nature07537

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 199

  WalkerJABarlowJLMcKenzieAN. Innate lymphoid cells – how did we miss them?Nat Rev Immunol (2013) 13:75–87.10.1038/nri3349

  • CrossRef
  • Google Scholar

• 200

  KloverprisHNKazerSWMjosbergJMabukaJMWellmannANdhlovuZet alInnate lymphoid cells are depleted irreversible during acute HIV-1 infection in the absence of viral suppression. Immunity (2016) 44:391–405.10.1016/j.immuni.2016.01.006

  • CrossRef
  • Google Scholar

• 201

  GenoveseLNebuloniMAlfanoM. Cell-mediated immunity in elite controllers naturally controlling HIV viral load. Front Immunol (2013) 4:86.10.3389/fimmu.2013.00086

  • Pubmed Abstract
  • CrossRef
  • Google Scholar